Advertisement
Product › Details
EBX-102-02 (EnteroBiotix)
Next higher product group | microbiomic treatment (live biotherapeutic product, LBP) | |
Status | 2024-04-04 development p2 planned | |
Organisation | EnteroBiotix Ltd. | |
EnteroBiotix Ltd.. (4/4/24). "Press Release: EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials". Glasgow.
EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the Company has completed its £27m ($34m USD) funding round, supported by new and existing investors. The funding will be used to advance EBX’s lead product candidate, EBX-102-02 through a Phase 2 clinical trial in Irritable Bowel Syndrome (‘IBS’) in partnership with the Functional Gut Clinic, as well as to progress its pipeline for other conditions linked to a disrupted gut microbiome, including liver cirrhosis and hepatic encephalopathy (‘HE’).
The financing, which comprises £15.7m of new equity and the conversion of £11.6m of loan notes into equity comes from experienced US-based life science investors Thairm Bio and Kineticos Life Sciences, as well as the Scottish National Investment Bank (‘the Bank’). Existing investors including Scottish Enterprise and many of the Company’s private investors also participated.
Dr James McIlroy, CEO of EnteroBiotix, said: “This significant new investment helps enable our vision of transforming the standard of care for patients suffering from serious conditions linked to the gut microbiome. It will help accelerate the development of our innovative product pipeline and propels us towards our goal of bringing these innovative treatments to market. We look forward to working closely with our new partners at the Bank and with our existing investors to bring this vision to fruition, for the benefit of patients across the globe.”
Record changed: 2024-04-07 |
Advertisement
More documents for microbiomic treatment (live biotherapeutic product, LBP)
- [1] EnteroBiotix Ltd.. (4/3/24). "Press Release: EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)". Glasgow....
- [2] EnteroBiotix Ltd.. (2/1/24). "Press Release: EnteroBiotix Strengthens Its Executive Team, Appoints COO and CFO". Glasgow....
- [3] Microbiotica Ltd.. (3/7/22). "Press Release: Microbiotica Raises £50 Million ($67 Million) to Advance Pipeline of Microbiome-based Therapeutics". Cambridge....
- [4] EnteroBiotix Ltd.. (9/7/21). "Press Release: EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline". Glasgow....
- [5] Prokarium Ltd.. (10/27/20). "Press Release: Prokarium Closes $21M Series B Financing Round and Strengthens Board". London....
- [6] 4D Pharma plc. (10/8/19). "Press Release: 4D Pharma Collaborates with MSD to Develop Live Biotherapeutics for Vaccines"....
- [7] Seventure Partners. (3/1/19). "Press Release: Seventure Partners Life Sciences Corporate Update September 2018 – February 2019". Paris....
- [8] Vedanta Biosciences. (12/24/18). "Press Release: Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates". Cambridge, MA....
- [9] A-Mansia Biotech S.A.. (4/27/18). "Press Release: Belgian Microbiome Spin-off A-Mansia Announces €13m First Close of Series A Financing". Louvain-la-Neuve....
- [10] Microbiotica Ltd.. (5/9/17). "Press Release: Microbiotica Appoints John Shields as Non-Executive Director"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top